FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for predicting the course of low-grade glial tumors based on a cytokine microenvironment, consisting in the fact that in the tumor tissue by the immunoenzymometric analysis the complex content of interleukins IL-4, IL-6, IL-8 is determined, and with their total IL-4 content within 0.5 to 1.4 pg/ml/g of protein, IL-6 from 4.4 to 50.6 pg/ml/g of protein, IL-8 from 43.7 to 125.2 pg/ml/g of protein predicted early tumor progression within 7-14 months after operation, and with their total content of IL-4 ranging from 13.1 to 28.2 pg/ml/g protein, IL-6 from 0 to 8.2 pg/ml/g protein, IL-8 from 0.3 to 19.6 pg/ml/g of the protein, progression is predicted more than 14 months after the operation.
EFFECT: invention provides predicting the course of low-grade glial tumors based on their cytokine microenvironment.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR RECURRENCE PREDICTION IN PATIENTS WITH BRAIN GLIOMAS | 2022 |
|
RU2776231C1 |
METHOD FOR DETECTING PROPERTIES OF HUMAN GLIOBLASTOMA MITOCHONDRIA TO INDUCE EXTRACRANIAL DIFFUSE TUMOR GROWTH IN THE ORGANS OF EXPERIMENTAL ANIMALS | 2023 |
|
RU2794641C1 |
METHOD FOR PREDICTING THE EFFECTIVENESS OF ADJUVANT INTERFERON THERAPY OF SKIN MELANOMA | 2019 |
|
RU2722403C1 |
METHOD FOR INDICATING THE EFFECTIVENESS OF COMBINED ADAPTIVE STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN MEN WITH MALIGNANT BRAIN GLIOMAS | 2023 |
|
RU2801419C1 |
METHOD OF CALCULATION OF FORECAST FOR EARLY DEVELOPMENT OF SKIN MELANOMA | 2017 |
|
RU2643761C1 |
METHOD FOR PREDICTING RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER | 2022 |
|
RU2793510C1 |
METHOD FOR ASSESSING RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-VEGF THERAPY | 2024 |
|
RU2823505C1 |
TEST SYSTEM FOR DETERMINING IDH 1/2 GENE STATUS IN GLIAL TUMOR TISSUES | 2023 |
|
RU2823028C1 |
METHOD FOR DIAGNOSING GLIAL BRAIN TUMORS OF HIGH DEGREE OF MALIGNANCY | 2020 |
|
RU2742413C1 |
METHOD FOR PREDICTION OF PERITONEAL METASTASES OF GASTRIC CANCER | 2018 |
|
RU2686689C1 |
Authors
Dates
2021-01-28—Published
2020-06-08—Filed